Title: Bendectin and birth defects
First published: 1996
Description: Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.
Subjects: Abnormalities, Human, Bendectin (Trademark), Complex litigation, Drugs, Human Abnormalities, Products liability, Toxic torts, Toxicology, Pyridoxine, Adverse effects, Doxylamine, Abnormalities, Drug-Induced, Legislation, Consumer Product Safety
Places: United States
LC classification: KF1297.D7 G74 1996